Sweetech, a biotech based on the INSA Toulouse campus, announced on 8 January 2026 the closing of a €2.25 million seed round. The round is led by Iron Hands Capital and Bpifrance. Co-founded in 2021 by Julien Durand, the company develops a patented platform for producing oligosaccharides — “rare sugars” — through microbial fermentation.
€2.25M to move from the lab to pilot production
The deal, reported by Le Journal des Entreprises, follows a €250,000 pre-seed closed in 2023 with five specialist business angels. With this €2.25M, Sweetech is entering a controlled industrialization phase.
Three priorities shape how the funds will be used:
- Launching pilot production as early as 2026, a prerequisite for moving from samples to the first commercial contracts.
- Developing the client portfolio across three markets: cosmetics, nutraceuticals and pharmaceuticals.
- Strengthening R&D and expanding the range of target molecules.
The team currently numbers eight, a headcount set to grow steadily as the pilot plants come online.
What are rare sugars, and why are they so hard to produce?
Oligosaccharides, or "rare sugars", are short sugar chains found in very small quantities in nature. Tagatose, D-allulose and human milk oligosaccharides (HMOs, Human Milk Oligosaccharides) are the best-known examples. Extracting them from natural sources is costly, sometimes ethically contentious, and limited in volume.
The precision fermentation route — the one taken by Sweetech — uses optimized micro-organisms to produce these molecules reproducibly and at controlled cost. According to NutraIngredients, fermentation has become the reference route for commercial HMOs such as 2'-fucosyllactose, now found in the majority of premium infant formulas.
Market: a fast-growing segment
The global rare sugars market is worth $2.3 billion in 2025 and is expected to reach $4.65 billion by 2035, a CAGR of 7.3% according to Market Research Future. The HMO sub-segment is growing even faster. MarketsandMarkets projects annual growth of 14% to 22% through 2034.
This momentum comes down to three drivers:
- Favorable regulation on the food industry side (EFSA and FDA approvals for several HMOs since 2018).
- Cosmetic demand for natural actives that are traceable and compatible with clean beauty standards.
- Pharma pipeline using oligosaccharides as adjuvants or carriers for active ingredients.
Competition: a landscape dominated by Asian and Danish players
Sweetech is positioning itself against well-capitalized leaders:
- Chr. Hansen / Novonesis (Denmark): the historical benchmark in infant HMOs.
- DSM-Firmenich (Netherlands/Switzerland): large-scale industrial production following the acquisition of Glycom.
- Genechem (South Korea): new commercial production site for sialyllactose.
- Inbiose (Belgium): spin-off of Ghent University, extensive patent portfolio.
- Biological scale-up: moving from the lab to an industrial pilot remains the biggest point of failure for industrial biotechs. Fermentation yields often drop as volumes increase.
- Regulatory validation: each application market (cosmetics, nutraceuticals, pharma) requires its own dossiers, sometimes lengthy and costly.
- Competitive pricing pressure as Novonesis and DSM amortize their existing lines.
Sweetech's angle of attack is twofold: a fermentation cost claimed to be lower thanks to its proprietary strain, and a B2B niche strategy (premium cosmetics, pharma ingredients) rather than a head-on battle over infant formula.
Why Toulouse is fertile ground
Toulouse's industrial biotech ecosystem has grown denser around INSA, INRAE and the Toulouse White Biotechnology Centre. The region counts several recent successes (Cosmo Bio, Biomede) and benefits from operating costs significantly lower than in Paris or Lyon. The presence of Toulouse Tech Transfer, which supported the maturation of the project, is a positive signal about the quality of Sweetech's intellectual property.
Investor profile
Iron Hands Capital is a fund specialized in industrial deeptech, known for its seed-to-Series A tickets in green chemistry and bio-fabrication. Bpifrance is involved here through its French Tech Seed and Innovation programs, consistent with the usual pattern for this type of round: a matching lever that reassures LPs and accelerates subsequent closings.
For deeptech founders structuring their growth strategy with B2B industrial players, this co-investment is a reference worth studying — it typically secures the signing of a first industrial client within 12 to 18 months.
Execution risks
Three areas to watch:
Takeaways for industrial buyers
For R&D and procurement leadership at French cosmetics or nutraceutical brands, Sweetech offers a sovereignty lever. Premium functional ingredients today come mostly from Asia or Denmark: having a certified French supplier paves the way for traceable Made in France claims, an argument increasingly used by European DTC brands.
FAQ
What is the exact amount of Sweetech's raise?
Sweetech raised €2.25 million in seed funding on January 8, 2026, from Iron Hands Capital and Bpifrance. This round brings the company's total funding to around €2.5M since its founding in 2021.
What does Sweetech produce?
The biotech produces oligosaccharides — rare sugars — through patented microbial fermentation. These molecules target the cosmetics, nutraceutical, and pharmaceutical markets.
How big is the rare sugars market?
The global market is worth $2.3 billion in 2025 according to Market Research Future, with growth expected to reach $4.65 billion by 2035. The HMO sub-segment is growing even faster, at a CAGR of between 14% and 22%.
Who are Sweetech's main competitors?
Novonesis (formerly Chr. Hansen), DSM-Firmenich, Genechem, and Inbiose currently dominate the global market. Sweetech positions itself with a B2B niche strategy and a claimed lower fermentation cost.
What will the funds be used for?
Three priorities: launching pilot production in 2026, developing the client portfolio across three application markets, and strengthening R&D and industrialization efforts.